China Biopharmaceutical Contract Manufacturing Market: Installed Capacity

Majority share (53%) of the biopharmaceutical contract manufacturing capacity in China is primarily driven by mid-sized companies. This can be attributed to relatively higher number of mid-sized players in the biopharmaceutical contract manufacturing market in China. Examples of Chinese biopharmaceutical contract manufacturers which were observed to have the highest capacity include (in decreasing order of capacity) WuXi AppTec, Asymchem, MabPlex, AutekBio, and GE Healthcare.

Over 80% of the current manufacturing capacity for biopharmaceutical in China is dedicated to commercial operations, while the remaining capacity is installed in companies operating at preclinical / clinical scales. This can be attributed to the growing number of expansion initiatives being carried out by several biopharmaceutical contract manufacturers in China to establish commercial scale manufacturing facilities.

Presently, the largest proportion (53%) of the overall biopharmaceutical manufacturing capacity is installed in facilities located in eastern China. This can be attributed to the fact that a large number of biopharmaceutical manufacturers are based in the aforementioned region. This is followed by the facilities based in northern China, where 18% of the overall capacity is installed.

Further, in northern China, eastern China, Hong Kong and Taiwan, majority (over 50%) of the capacity is occupied by large and very large companies. While in central China and southern China, majority of the capacity is installed in facilities of mid-sized players.

Currently, majority of the capacity in most of the regions of China is installed for carrying out commercial scale operations. It is worth highlighting that, in Hong Kong, 100% of the capacity is for preclinical / clinical scale of manufacturing, whereas in Taiwan, 100% capacity is dedicated to commercial scale production of biopharmaceuticals. Examples of CMOs having established facilities in Taiwan for carrying out commercial scale of manufacturing include (in alphabetical order) Adimmune, Amaran Biotechnology, EirGenix, JHL Biotech, Mycenax Biotech and ScinoPharm.

The 'China Biopharmaceutical Contract Manufacturing Market, 2020-2030' report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:

• A detailed review of the overall landscape of companies offering contract manufacturing services for biopharmaceuticals in China, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities, as well as location of these facilities, type of business segment, type of manufacturing service(s) offered (process development and characterization, method validation and testing, analytical development, stability studies, quality assurance and control, scale-up, downstream processing, regulatory support, data analytics and reporting, and others), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression system(s) used (mammalian, microbial and others), type of bioreactor(s) used (single-use bioreactors and stainless steel bioreactors) and its mode of operation (batch, fed-batch and perfusion), type of packaging, and affiliations to regulatory accreditations and certifications (if any).

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

• Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biotechnologie
• Jeffrey Hung, Chief Commercial Officer, Vigene Biosciences
• Stephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Roots Analysis provides market research and consulting in the pharmaceutical industry. Focussed on providing an informed and impartial view on key issues facing the industry, our research is primarily driven by an in-depth analysis.